Edit Symbol List
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
ETFs with TTPH as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|0.42%||Wilshire Micro-Cap ETF (based on the Wilshire US Micro-Cap Ind (WMCR)||-2.81 (-10.12%)|
Company Description (as filed with the SEC)
We are a clinical-stage biopharmaceutical company using our proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant infections. We are developing our lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a broad-spectrum intravenous, or IV, and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant Gram-negative infections. We are conducting a global Phase 3 clinical program for eravacycline called IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline), consisting of two Phase 3 clinical trials. IGNITE 1 is a Phase 3 clinical trial evaluating the safety and efficacy of eravacycline with IV administration for the treatment of complicated intra-abdominal infections, or cIAI, for which we announced top-line data in December 2014. ... More ...
Where does TTPH fit in the risk graph?
|Annual EPS Est:||$-2.49|
|Quarterly EPS Est:||-0.66|